It suggests that checkpoint inhibitors such as anti-PD-L1 or CTLA-4 may be able to result in a less MDSC-driven suppressive immune phenotype and improved function of graft (and host) T cells early post-transplant—at a time when the tumor microenvironment has been disrupted by intensive chemo/radiation therapy. This evidence concerns the gene CD274 and neoplasm.